Hapten-Modified Tumor Vaccines
Haptens are tiny lights that illuminate the dark recesses of the immune system. They were discovered by Karl Landsteiner, who used haptens to explore the breadth and fine sensitivity of antibody responses. Landsteiner (1) worked with a variety of simple chemicals, including nitrophenyls and phenyl arsonates, that were incapable of inducing an immune response by themselves, but became immunogenic when they were attached covalently to a protein carrier. He coined the term “hapten” from the Greek haptein, meaning to fasten.
KeywordsMajor Histocompatibility Complex Melanoma Cell Antigenic Determinant Purify Protein Derivative Sulfanilic Acid
Unable to display preview. Download preview PDF.
- 1.Landsteiner K. Artificial conjugated antigens. Serological reactions with simple chemical compounds. In: Anonymous. The specificity of serological reactions. New York: Dover, 1962:156–209.Google Scholar
- 3.Weigle WO. Termination of immunologic unresponsiveness. In: Weigle WO, ed. Natural and acquired immunologic unresponsiveness. Cleveland: World Publishing, 1967:57–173.Google Scholar
- 5.Raff MC. Surface antigenic markers for distinguishing T and B lymphocytes in mice. Transplant Res 1971; 6:52.Google Scholar
- 10.Little JR, Eisen HN. Preparation of immunogenic 2,4-dinitrophenyl and 2,4,6-trinitrophenyl proteins. In: Williams CA, Chase MW, eds. Methods in immunology and immunochemistry. New York: Academic, 1967:128–132.Google Scholar
- 14.Levy RB, Shearer GM, Richardson JC, Henkart PA. Cell-mediated lympholytic responses against autologous cells modified with haptenic sulfhydryl reagents. I. Effector cells can recognize two distinct classes of hapten-reactive self sites on cell surface proteins. J Immunol 1981; 127:523.PubMedGoogle Scholar
- 22.deWeck AL. Pharmacologic and immunochemical mechanisms of drug hypersensitivity. Immunol All Clin NA 1991; 11:461–474.Google Scholar
- 24.Gilliland BC. Drug-induced autoimmune and hematologic disorders. Immunol Allergy Clin North Am 1991; 11:525–553.Google Scholar
- 27.Mitchison NA. Immunologic approach to cancer. Transplant Proc 1970; 11:92–103.Google Scholar
- 60.Kirkwood JM, Ibrahim JG, Sosman JA, Sondak VK, Agarwala SS, Ernstoff MS, et al. High-dose interferon alfa-2b significantly prolongs relapse-free and overall survival compared with the GM2KLH/QS-21 vaccine in patients with resected stage IIB-Ill melanoma: results of intergroup trial E1694/ 59512/C509801. J Clin Oncol 2001; 19:2370–2380.PubMedGoogle Scholar
- 62.Berd D, Mastrangelo MJ, Sato T, Bloome E. Effectiveness of autologous, hapten-modified melanoma vaccine depends on the timing of an induction dose. Proc Am Assoc Cancer Res 2001; 42:683 (Abstract).Google Scholar